Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Seeks Performance Data From FDA On De Novos, Postmarket Surveillance

This article was originally published in The Gray Sheet

Executive Summary

A Senate panel directs FDA to meets its statutory deadlines for de novo reviews and device risk classifications of devices, and requests data on those programs – as well as for the agency's postmarket device surveillance activities – in a 2017 appropriations bill.

Advertisement

Related Content

FDA '522' Guidance: 15-Month Deadline To Comply With Postmarket Order
New Fundings And Goals To Match Raised In Latest MDUFA IV Session

Topics

Advertisement
UsernamePublicRestriction

Register

MT034799

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel